(Q33988376)

30 July 2017

1 reference

title

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review (English)

1 reference

30 July 2017

Second-Generation (Atypical) Antipsychotics and Metabolic Effects (English)

0 references

1 reference

John W Newcomer

1

1 reference

30 July 2017

John W. Newcomer

series ordinal

1

0 references

publication date

1 January 2005

1 reference

30 July 2017

2005

0 references

published in

CNS Drugs

1 reference

30 July 2017

19 Suppl 1

1 reference

30 July 2017

19

0 references

issue

Supplement 1

0 references

page(s)

1-93

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200519001-00001

30 July 2017

0 references

cites work

Differential effect of clozapine on weight: a controlled study.

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200519001-00001

Olanzapine increases weight and serum triglyceride levels.

21 January 2018

1 reference

12 December 2020

The mortality experience of individuals on the Salford Psychiatric Case Register. I. All-cause mortality

1 reference

12 December 2020

Clozapine and diabetic ketoacidosis

1 reference

12 December 2020

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

1 reference

12 December 2020

Diabetic ketoacidosis with olanzapine treatment

1 reference

12 December 2020

Abdominal obesity as important component of insulin-resistance syndrome

1 reference

12 December 2020

Diabetes mellitus in schizophrenic patients

1 reference

12 December 2020

Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses

1 reference

12 December 2020

A prospective study of body mass index, weight change, and risk of stroke in women.

1 reference

12 December 2020

A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents

1 reference

12 December 2020

New-onset diabetes mellitus associated with quetiapine

1 reference

12 December 2020

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

1 reference

12 December 2020

Hyperglycemia and antipsychotic medications.

1 reference

12 December 2020

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

12 December 2020

Review of atypical antipsychotics and weight gain.

1 reference

12 December 2020

Association of olanzapine-induced weight gain with an increase in body fat.

1 reference

12 December 2020

Syndrome X: 10 years after

1 reference

12 December 2020

Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine.

1 reference

12 December 2020

Medical hazards of obesity

1 reference

12 December 2020

Uncontrolled hyperglycemia with ketosis associated with olanzapine therapy

1 reference

12 December 2020

Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications

1 reference

12 December 2020

Atypical neuroleptics and diabetes

1 reference

12 December 2020

Severe hyperglycemia associated with high doses of clozapine

1 reference

12 December 2020

Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance

1 reference

12 December 2020

Body mass index and the prevalence of hypertension and dyslipidemia

1 reference

12 December 2020

Pathophysiology and treatment of the dyslipidemia of insulin resistance

1 reference

12 December 2020

Diabetic ketoacidosis with clozapine treatment

1 reference

12 December 2020

Elevated serum triglycerides with clozapine resolved with risperidone in four patients

1 reference

12 December 2020

Fatal olanzapine-induced ketoacidosis

1 reference

12 December 2020

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

12 December 2020

Diabetic ketoacidosis associated with clozapine treatment

1 reference

12 December 2020

Quetiapine-associated hyperglycemia and hypertriglyceridemia

1 reference

12 December 2020

Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial

1 reference

12 December 2020

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

1 reference

12 December 2020

Fatality from olanzapine induced hyperglycemia.

1 reference

12 December 2020

Dosing the antipsychotic medication olanzapine

1 reference

12 December 2020

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

12 December 2020

Weight gain among schizophrenic patients treated with clozapine

1 reference

12 December 2020

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

1 reference

12 December 2020

Risperidone-associated new-onset diabetes

1 reference

12 December 2020

Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake

1 reference

12 December 2020

Diabetes mellitus induced by olanzapine. A case report

1 reference

12 December 2020

Weight gain and hyperglycaemia associated with olanzapine

1 reference

12 December 2020

Olanzapine-induced elevation of plasma triglyceride levels

1 reference

12 December 2020

The effects of novel antipsychotics on glucose and lipid levels.

1 reference

12 December 2020

Olanzapine treatment of eight adolescent patients with psychosis

1 reference

12 December 2020

A neurobiological basis for substance abuse comorbidity in schizophrenia

1 reference

12 December 2020

A placebo-controlled trial of risperidone in Tourette syndrome

1 reference

12 December 2020

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

1 reference

12 December 2020

The distribution of body mass index among individuals with and without schizophrenia.

1 reference

12 December 2020

Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy

1 reference

12 December 2020

Near fatal ketoacidosis with olanzapine treatment

1 reference

12 December 2020

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

1 reference

12 December 2020

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

12 December 2020

Body weight gain induced by antipsychotic drugs: mechanisms and management

1 reference

12 December 2020

A review of the effect of atypical antipsychotics on weight

1 reference

12 December 2020

Diabetic ketoacidosis associated with clozapine treatment

1 reference

12 December 2020

[Hyperglycemia and ketoacidosis associated with olanzapine]

1 reference

12 December 2020

Deaths: final data for 2000.

1 reference

12 December 2020

Diagnosis, classification, and pathogenesis of diabetes mellitus.

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Deaths from diabetic ketoacidosis after long-term clozapine treatment

1 reference

12 December 2020

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

1 reference

12 December 2020

Clozapine use and risk of diabetes mellitus

1 reference

12 December 2020

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

1 reference

12 December 2020

Amisulpride is an "atypical" antipsychotic associated with low weight gain

1 reference

12 December 2020

Atypical antipsychotics and weight gain--a systematic review

1 reference

12 December 2020

Weight gain as a risk factor for clinical diabetes mellitus in women.

1 reference

12 December 2020

Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation.

1 reference

12 December 2020

Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine

1 reference

12 December 2020

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

1 reference

12 December 2020

Physical health monitoring of patients with schizophrenia

1 reference

12 December 2020

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

12 December 2020

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

12 December 2020

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone

1 reference

12 December 2020

The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists

1 reference

12 December 2020

Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly

1 reference

12 December 2020

Olanzapine induces insulin resistance: results from a prospective study

1 reference

12 December 2020

Olanzapine: weight gain and therapeutic efficacy

1 reference

12 December 2020

Olanzapine-induced diabetes mellitus

1 reference

12 December 2020

Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

1 reference

12 December 2020

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

1 reference

12 December 2020

Clozapine: a clinical review of adverse effects and management

1 reference

12 December 2020

Abnormalities in glucose regulation associated with mental illness and treatment

1 reference

12 December 2020

Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia

1 reference

12 December 2020

Diabetic ketoacidosis associated with olanzapine in an adolescent patient

1 reference

12 December 2020

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

1 reference

12 December 2020

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement

1 reference

12 December 2020

Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study

1 reference

12 December 2020

Weight variance associated with atypical neuroleptics in nursing home dementia patients

1 reference

12 December 2020

Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells

1 reference

12 December 2020

The unhealthy lifestyle of people with schizophrenia

1 reference

12 December 2020

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

12 December 2020

Clozapine-associated elevation in serum triglycerides

1 reference

12 December 2020

Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

1 reference

12 December 2020

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

1 reference

12 December 2020

Clozapine and associated diabetes mellitus

1 reference

12 December 2020

Weight stability masks sarcopenia in elderly men and women

1 reference

12 December 2020

Schizophrenia and diabetes mellitus

1 reference

12 December 2020

The safety and efficacy of zotepine in the treatment of schizophrenia: Results of a one-year naturalistic clinical trial

1 reference

12 December 2020

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health

1 reference

12 December 2020

Mechanism of peripheral noradrenergic stimulation by clozapine.

1 reference

12 December 2020

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

1 reference

12 December 2020

Olanzapine-induced glucose dysregulation.

1 reference

12 December 2020

The apparent effects of ziprasidone on plasma lipids and glucose.

1 reference

12 December 2020

Clozapine-induced weight gain: prevalence and clinical relevance

1 reference

12 December 2020

Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors

1 reference

12 December 2020

The clinical implications of weight gain in schizophrenia.

1 reference

12 December 2020

Excess mortality in depression: a meta-analysis of community studies.

1 reference

12 December 2020

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

12 December 2020

Novel antipsychotics: comparison of weight gain liabilities.

1 reference

12 December 2020

Annual Deaths Attributable to Obesity in the United States

1 reference

12 December 2020

Clozapine monotherapy and ketoacidosis

1 reference

12 December 2020

Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications

1 reference

12 December 2020

The effect of clozapine on glucose metabolism.

1 reference

12 December 2020

Olanzapine-induced diabetic ketoacidosis

1 reference

12 December 2020

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

1 reference

12 December 2020

Excess mortality of schizophrenia. A meta-analysis

1 reference

12 December 2020

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

1 reference

12 December 2020

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

1 reference

12 December 2020

Resolution of hyperglycemia on risperidone discontinuation: a case report.

1 reference

12 December 2020

Clozapine-induced diabetic ketoacidosis

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

12 December 2020

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

12 December 2020

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

12 December 2020

Mortality of patients with mood disorders: follow-up over 34-38 years

1 reference

12 December 2020

The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.

1 reference

12 December 2020

Clozapine-associated diabetes

1 reference

12 December 2020

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

12 December 2020

Weight as a risk factor for clinical diabetes in women.

1 reference

12 December 2020

Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia an underestimated evil?

1 reference

12 December 2020

Diabetic ketoacidosis from clozapine and lithium cotreatment

1 reference

12 December 2020

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

1 reference

12 December 2020

Schizophrenia and diabetes mellitus: not an improbable combination

1 reference

12 December 2020

Insulin resistance: from benign to type 2 diabetes mellitus

1 reference

12 December 2020

Lactic acidosis and fatal myocardial failure due to clozapine.

1 reference

12 December 2020

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

1 reference

12 December 2020

Report of the expert committee on the diagnosis and classification of diabetes mellitus

1 reference

12 December 2020

No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment.

1 reference

12 December 2020

Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts

1 reference

12 December 2020

Olanzapine-induced ketoacidosis with diabetes mellitus

1 reference

12 December 2020

Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine

1 reference

12 December 2020

Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)?

1 reference

12 December 2020

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

1 reference

12 December 2020

Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study

1 reference

12 December 2020

1 reference

12 December 2020

Is glucose a continuous risk factor for cardiovascular mortality?

1 reference

12 December 2020

Olanzapine-associated diabetes mellitus

1 reference

12 December 2020

New-onset diabetes and ketoacidosis with atypical antipsychotics

1 reference

12 December 2020

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

1 reference

12 December 2020

Insulin-resistant hyperglycemia induced by clozapine.

1 reference

12 December 2020

Diagnosis and classification of diabetes mellitus

1 reference

12 December 2020

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

1 reference

12 December 2020

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Eruptive xanthomas associated with olanzapine use.

1 reference

12 December 2020

Role of brain insulin receptor in control of body weight and reproduction

1 reference

12 December 2020

Hyperglycemia and hypertriglyceridemia secondary to olanzapine

1 reference

12 December 2020

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

12 December 2020

Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.

1 reference

12 December 2020

Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder.

1 reference

12 December 2020

Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy

1 reference

12 December 2020

Olanzapine-lnduced hyperglycemic nonketonic coma

1 reference

12 December 2020

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals

1 reference

12 December 2020

A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States

1 reference

12 December 2020

Recovery from new-onset diabetes in a schizophrenic man after withdrawal of olanzapine

1 reference

12 December 2020

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

12 December 2020

The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease

1 reference

12 December 2020

Effects of weight loss on regional fat distribution and insulin sensitivity in obesity

1 reference

12 December 2020

The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.

1 reference

12 December 2020

A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus.

1 reference

12 December 2020

A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder

1 reference

12 December 2020

Olanzapine-associated type 2 diabetes mellitus

1 reference

12 December 2020

Pregnancy of a patient treated with clozapine

1 reference

12 December 2020

The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients

1 reference

12 December 2020

Antipsychotic-induced type 2 diabetes: evidence from a large health plan database

1 reference

12 December 2020

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

1 reference

12 December 2020

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

1 reference

12 December 2020

New-onset diabetes mellitus associated with the initiation of quetiapine treatment

1 reference

12 December 2020

Hyperglycemia associated with olanzapine

1 reference

12 December 2020

1 reference

12 December 2020

Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis.

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Novel antipsychotics and severe hyperlipidemia

1 reference

12 December 2020

Diabetes mellitus after treatment with clozapine

1 reference

12 December 2020

Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia

1 reference

12 December 2020

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

1 reference

12 December 2020

Severe weight gain induced by combination treatment with risperidone and paroxetine

1 reference

12 December 2020

Revealing the cost of Type II diabetes in Europe.

1 reference

12 December 2020

Potential risk of diabetes mellitus with the use of atypical antipsychotic medication

1 reference

12 December 2020

The continuing epidemics of obesity and diabetes in the United States

1 reference

12 December 2020

Low-Dose Clozapine and Diabetic Ketoacidosis

1 reference

12 December 2020

Diabetic ketoacidosis and clozapine

1 reference

12 December 2020

Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone

1 reference

12 December 2020

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

1 reference

12 December 2020

Weight gain: side effect of atypical neuroleptics?

1 reference

12 December 2020

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

1 reference

12 December 2020

Bodyweight gain with atypical antipsychotics. A comparative review

1 reference

12 December 2020

Type 2 Diabetes Mellitus Induced by an Atypical Antipsychotic Medication

1 reference

12 December 2020

A study of quetiapine: efficacy and tolerability in psychotic adolescents

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

DRUG-PRODUCED OBESITY. EXPERIENCES WITH CHLORPROMAZINE, PERPHENAZINE AND CLOPENTHIXOL

1 reference

12 December 2020

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

12 December 2020

Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range.

1 reference

12 December 2020

Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.

1 reference

12 December 2020

Body size and fat distribution as predictors of stroke among US men.

1 reference

12 December 2020

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

1 reference

12 December 2020

Biomedicine. Staying slim with insulin in mind

1 reference

12 December 2020

One- and two-year change in body composition as measured by DXA in a population-based cohort of older men and women

1 reference

12 December 2020

Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive?

1 reference

12 December 2020

Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature

1 reference

12 December 2020

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Olanzapine-induced diabetes mellitus

1 reference

12 December 2020

Ketoacidosis as a side-effect of clozapine: a case report

1 reference

12 December 2020

Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome

1 reference

12 December 2020

Economic costs of diabetes in the US in 2002.

1 reference

12 December 2020

A comparative review of new antipsychotics

1 reference

12 December 2020

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database

1 reference

12 December 2020

Serum triglyceride levels in patients treated with clozapine

1 reference

12 December 2020

Atypical antipsychotic drug use and diabetes

1 reference

12 December 2020

Diabetes as a result of atypical anti-psychotic drugs--a report of three cases

1 reference

12 December 2020

Novel antipsychotics and new onset diabetes

1 reference

12 December 2020

Euglycemic clamp study in clozapine-induced diabetic ketoacidosis

1 reference

12 December 2020

Risperidone in children with autism and serious behavioral problems

1 reference

12 December 2020

Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan

1 reference

12 December 2020

Hyperglycemia, hyperlipemia, and periodic paralysis: a case report of new side effects of clozapine

1 reference

12 December 2020

Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment

1 reference

12 December 2020

Management of dyslipidemia: an update

1 reference

12 December 2020

The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

12 December 2020

The impact of clozapine treatment on serum lipids in chronic schizophrenic patients

1 reference

12 December 2020

Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents

1 reference

12 December 2020

Diabetic ketoacidosis associated with risperidone treatment?

1 reference

12 December 2020

Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study

1 reference

12 December 2020

Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report.

1 reference

12 December 2020

Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment.

1 reference

12 December 2020

A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia

1 reference

12 December 2020

A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year

1 reference

12 December 2020

Risperidone-associated diabetes mellitus: a pharmacovigilance study

1 reference

12 December 2020

Open-label study of olanzapine in children with pervasive developmental disorder

1 reference

12 December 2020

Mortality and causes of death in schizophrenia in Stockholm county, Sweden

1 reference

12 December 2020

[Heart failure due to metabolic heart disorders]

1 reference

12 December 2020

Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine

1 reference

12 December 2020

Prevalence and correlates of diabetes in national schizophrenia samples.

1 reference

12 December 2020

Phenothiazines and Diabetes in Hospitalized Women

1 reference

12 December 2020

Olanzapine-induced destabilization of diabetes in the absence of weight gain

1 reference

12 December 2020

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

1 reference

12 December 2020

Diabetes mellitus associated with clozapine therapy

1 reference

12 December 2020

Characteristics of diabetes mellitus in schizophrenic patients

1 reference

12 December 2020

Olanzapine and hypertriglyceridemia

1 reference

12 December 2020

Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature

1 reference

12 December 2020

Severe hypertriglyceridemia associated with olanzapine.

1 reference

12 December 2020

Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993

1 reference

12 December 2020

Hyperglycemia and olanzapine

1 reference

12 December 2020

The effect of clozapine on blood glucose metabolism

1 reference

12 December 2020

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

12 December 2020

10.2165/00023210-200519001-00001

Identifiers

DOI

0 references

Dimensions Publication ID

0 references

1 reference